IMU Biosciences logo

IMU Biosciences

Blood-based immune profiling startup decoding immunity from a single sample. Latest 2026 funding round details, biotech AI sector insights inside.

AI Developer Tools
General
Total Raised
$53M
Last Valuation
$353M
Headquarters
London, UK

Overview

IMU Biosciences is a London biotech developing technology to decode the immune system using a single blood sample. Its work is positioned for biotechnology and healthcare organizations seeking richer immune-system insight from minimally invasive sampling. The company’s stated differentiator is its single-sample approach to immune profiling, which could support research and clinical applications where immune status is important. IMU Biosciences raised $53 million in an undisclosed round announced in June 2026.

Funding History

1 round · Jun 2026
$53M
Total Raised
1
Valuation: $353M
Cumulative: $53M

London biotech raises $53M to decode the immune system using a single blood sample

IQ Capital (Lead)Molten Ventures (Lead)British Business BankMeltwind
Source

Frequently Asked Questions

How much has IMU Biosciences raised in total?
IMU Biosciences has raised a total of $53M across 1 funding round.
Who are IMU Biosciences's investors?
IMU Biosciences's investors include IQ Capital, Molten Ventures, British Business Bank, Meltwind.
What does IMU Biosciences do?
IMU Biosciences is a London biotech developing technology to decode the immune system using a single blood sample. Its work is positioned for biotechnology and healthcare organizations seeking richer immune-system insight from minimally invasive sampling. The company’s stated differentiator is its single-sample approach to immune profiling, which could support research and clinical applications where immune status is important. IMU Biosciences raised $53 million in an undisclosed round announced in June 2026.
Where is IMU Biosciences headquartered?
IMU Biosciences is headquartered in London, UK.